{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:56:38Z","timestamp":1792065398614,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dld.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:19:21Z","timestamp":1791026361000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-na\u00efve Crohn\u2019s disease: Analysis from a real-world cohort"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-1133","authenticated-orcid":false,"given":"Uria","family":"Shani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Yaakobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-6903","authenticated-orcid":false,"given":"Haim","family":"Leibovitzh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-0024","authenticated-orcid":false,"given":"Nitsan","family":"Maharshak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya Mushka","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-4263","authenticated-orcid":false,"given":"Ahmad","family":"Albshesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-6550","authenticated-orcid":false,"given":"Offir","family":"Ukashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.09.009_bib0001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"10.1016\/j.dld.2026.09.009_bib0002","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.09.009_bib0003","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.09.009_bib0004","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/MCG.0000000000002056","article-title":"Real-world clinical effectiveness and safety of vedolizumab and Adalimumab in biologic-naive patients with Crohn\u2019s disease: results from the EVOLVE study","volume":"59","author":"Yarur","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.009_bib0005","first-page":"172","article-title":"Comparative effectiveness of infliximab vs Ustekinumab for endoscopic and transmural remission in biologic Na\u00efve Crohn\u2019s disease","volume":"24","author":"Huang","year":"2026","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.dld.2026.09.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102337","article-title":"Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-na\u00efve or anti-TNF-exposed Crohn\u2019s disease: a multicenter cohort study","volume":"66","author":"Yang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.dld.2026.09.009_bib0007","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12876-023-02723-5","article-title":"Comparison of surgery rates in biologic-na\u00efve patients with Crohn\u2019s disease treated with vedolizumab or ustekinumab: findings from SOJOURN","volume":"23","author":"Vu","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.009_bib0008","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.09.009_bib0009","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.09.009_bib0010","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.dld.2026.09.009_bib0011","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and Safety of Guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 GRAVITI Study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.09.009_bib0012","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.16742","article-title":"A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn\u2019s disease. The cross Pennine study II","volume":"55","author":"Lenti","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.09.009_bib0013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/MEG.0000000000002411","article-title":"Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn\u2019s disease: real-life cohort from a tertiary referral center","volume":"34","author":"Moens","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.009_bib0014","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.cgh.2021.04.006","article-title":"Comparative efficacy and rapidity of action for infliximab vs Ustekinumab in biologic Na\u00efve Crohn\u2019s disease","volume":"20","author":"Narula","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.009_bib0015","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/ibd\/izac271","article-title":"Real-world comparative effectiveness of Ustekinumab vs Anti-TNF in Crohn\u2019s disease with propensity score adjustment: induction phase results from the prospective, observational RUN-CD study","volume":"29","author":"Bokemeyer","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.09.009_bib0016","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12876-024-03403-8","article-title":"Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-na\u00efve and bio-experienced Crohn\u2019s disease patients: a retrospective multicenter study","volume":"24","author":"Na","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.009_bib0017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ibd\/izac167","article-title":"Comparative effectiveness of Ustekinumab and Anti-TNF agent as first-line biological therapy in luminal Crohn\u2019s disease: a retrospective study from 2 referral centers","volume":"29","author":"Rivi\u00e8re","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.09.009_bib0018","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ibd\/izad138","article-title":"Real-world effectiveness of Vedolizumab vs anti-TNF in biologic-na\u00efve Crohn\u2019s disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-study","volume":"30","author":"Bokemeyer","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.09.009_bib0019","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ueg2.12705","article-title":"Effectiveness and treatment persistence of Vedolizumab compared to anti-Tumour necrosis factor-\u03b1 in patients with Crohn\u2019s disease: a systematic literature review and meta-analysis. united","volume":"13","author":"Armuzzi","year":"2025","journal-title":"Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2026.09.009_bib0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.09.009_bib0021","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.09.009_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284820979765","article-title":"Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease","volume":"13","author":"Pauwels","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.009_bib0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal Calprotectin correlates more closely with the simple endoscopic score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"10.1016\/j.dld.2026.09.009_bib0024","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.09.009_bib0025","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.cgh.2020.08.022","article-title":"Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with crohn\u2019s disease","volume":"19","author":"Plevris","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.009_bib0026","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.09.009_bib0027","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.09.009_bib0028","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/apt.18006","article-title":"Meta-analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease","volume":"59","author":"Yiu","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.09.009_bib0029","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the persistence Australian national IBD cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.09.009_bib0030","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.cgh.2022.10.029","article-title":"Comparative Safety and Effectiveness of Biologic Therapy for Crohn\u2019s Disease: a CA-IBD Cohort Study","volume":"21","author":"Singh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.57922","article-title":"Comparative safety of advanced therapies for Crohn disease","volume":"9","author":"Park","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2026.09.009_bib0032","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600962X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600962X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:31:38Z","timestamp":1792063898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582600962X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S159086582600962X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.09.009","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-na\u00efve Crohn\u2019s disease: Analysis from a real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}